ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining

Merck & Co. has failed in an attempt to repeat Keytruda’s metastatic head and neck cancer success in locally advanced disease. But experts still see reasons to keep their hopes up for the drug in early stages of this tumor type.